phase 4 trials with TNF blockers in non-radiographic axial spondyloarthritis. An appropriately designed and powered long-term trial is needed to investigate possible long-term benefits and risks of treatment tapering in axial spondyloarthritis. Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7741

FRIDAY, 15 JUNE 2018

Prevention of OA: yes we can!

**SP0123** WHY IS THE PREVALENCE OF KNEE OSTEOARTHROSIS INCREASING?

D. Felson. Clinical Epidemiology Unit, Boston University School of Medicine, Boston, USA

Invited speaker abstract submission

EULAR18-7734

WHY IS THE PREVALENCE OF KNEE OSTEOARTHROSIS INCREASING?

D. Felson

I will give my lecture on: Friday, 15 June 2018

Disclosures of Interest: None declared

Populations throughout the world are ageing and with ageing comes in increase in knee osteoarthritis. The prevalence of obesity is also rising and this further contributes to an increased risk of disease. Not surprisingly, the demand for knee replacements is rising quickly and is projected to increase further. While the increase in osteoarthritis may be due in part to ageing and obesity of the population, there may be other causes. In a recent study, cadavers whose age and weight at the time of death were known were examined for evidence of knee osteoarthritis. It was found that, after adjustment for age and weight, knee osteoarthritis in our current postindustrial era was twice as common as knee osteoarthritis in the early industrial era. Reasons for this increase include changes in diet or in physical activity. They might also include changes in effects or severity of obesity. Understanding the increase in prevalence might provide new clues to osteoarthritis prevention.

Disclosure of Interest: None declared


**SP0124** PHYSICAL ACTIVITY AND EXERCISE: OPPORTUNITIES AND CHALLENGES

M. Englund. Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Osteoarthritis (OA) is a steadily growing public health concern in particular as there is still a lack of curative therapeutic options in a biological sense. Thus, prevention of OA becomes an increasingly important topic. Physical activity, and exercise are among the key modifiable risk factors associated with OA. Joints are built to be used, but overuse and joint injuries are also linked with incident OA. This presentation will provide some key opportunities with exercise to maintain joint health, but also the challenges when the window of opportunity is exceeded.

Disclosure of Interest: None declared


FRIDAY, 15 JUNE 2018

Big data for musculoskeletal research

**SP0125** HOW BIG DATA AND MACHINE LEARNING COULD CHANGE THE GAME


With recent advances in the acquisition and digitisation of medical data, the use of routinely collected health data for research is on the rise. Routinely collected data comes with the promise of the 3 V’s of “big data”: volume, velocity, and variety. Recent recommendations by the UK National Institute for Health and Care Excellence and the Academy of Medical Sciences have therefore acknowledged the potential for data science methods to play an increasingly important role in health-care research.

Against this backdrop of growing data and increasing computational resources, the use of data science methods including machine learning is becoming popular for analysing large-scale medical datasets. This talk provides a brief overview of machine learning methods for healthcare applications including an introduction to supervised and unsupervised learning, followed by real-world examples of data analysis using machine learning, such as (a) the development of prognostic models for clinical risk assessment, and (b) mining of electronic health records for detecting patterns and phenotypes within a population.

Disclosure of Interest: None declared


**SP0126** BIG DATA FOR TREATMENT EFFECTIVENESS AND SAFETY

L. Tomlinson. Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

While randomised clinical trials remain the gold-standard for examining drug-effects, there are limitations to the evidence they provide. For example, studies are usually too small or too short to detect rare and long-term adverse effects. This is particularly true for kidney-related outcomes where many trials were underpowered to detect outcomes of interest such as end-stage renal disease, too historic to collect data on newly-defined entities such as acute kidney injury or simply excluded patients with chronic kidney disease. In addition, disproportionate recruitment of Caucasian men in mid- to older-life limits the evidence base for understanding risk of adverse-effects in other population groups such as women, the elderly and people of non-Caucasian ethnicity. Determining these outcomes requires long-term surveillance of population databases, usually anonymised health care records, once a drug is in routine use. In this talk I will discuss recent work from our group where we have used routinely collected renal function measurements from primary care to precisely examine kidney-related and other adverse effects. I will discuss some of the difficulties of this approach as well as the potential it offers to understand better the balance between risks and benefits of many drugs in common use.

Disclosure of Interest: None declared


FRIDAY, 15 JUNE 2018

From big data to personalised medicine in paediatric rheumatic diseases

**SP0127** FROM MENDELIOME TO PERSONALISED MEDICINE IN CHILDHOOD SLE

A. Belot1,2, on behalf of Genial/Lumene working group. 1Pediatric Rheumatology Unit – National Referre Centre for Rheumatism and Autoimmune diseases – Raise, Chu Lyon; 2U1111, INSERM, Lyon, France

Pediatric-onset SLE is a rare condition where genetics traits are believed to play an important causal role. A few monogenic causes of SLE have been described mostly in familial forms, including complement deficiencies, so-called type I interferonopathies, and B cell-related defects. Genetic studies in mouse models and genome-wide associations studies in patients have also pointed to other genes potentially involved in juvenile SLE. However, large-scale sequencing analyses of paediatric SLE are lacking, and the overall contribution of genetic factors in disease onset is therefore unknown. Personalised medicine relies on the understanding of underlying mechanisms. Genetic discovery and functional characterization of the variants prefigure the precision medicine in complex diseases such as SLE.

We have designed a NGS panel comprising genes for which mutations are known lupus causal (KLC) (also reported as the Mendeliope) as well as prospective candidate genes, potentially lupus causing (PLC), and analysed 117 children who fulfilled ACR criteria for SLE from two large cohorts of pediatric-onset SLE in the UK and France. Genetic variants were identified and filtered to select rare (ExAC database frequency of <1% for homozygous variants and <0.01% for heterozygous variants) and predicted in silico as damaging by different algorithms.

We identified mutations in KLC genes for 8 patients. Variant segregation within families and functional analyses supported the causal role of these mutations. Other patients had monoallelic variants in recessive KLC genes, which may have contributed to disease onset and other patients displayed rare and pathogenic variants in PLC genes. This enrichment was specific to the lupus cohort compared to a control cohort of healthy patients.
This large-scale analysis led to the identification of monogenic causes of lupus in about 7% of analysed patients in an unselected paediatric population of SJLE. 7/8 causes are related to an innate immune disorder with effectorcytosis deficiency, emphasising the importance of apoptotic body clearance in the pathogenesis of lupus. Other variants in KLC or PLC genes may represent novel monogenic causes of lupus or could influence disease-onset by increasing the penetrance of more severe mutations. The treatment is still poorly adapted to the underlying mechanisms but progress in immunomonitoring together with the revolution in the field of genetics prompt clinicians to set up targeted therapies considering genetic background and biomarkers.

Disclosure of Interest: A. Belot

Grant/research support from: MERCK


SP0128

FINDING THE NEEDLE IN THE HAYSTACK AND USING IT: GALECTIN-9 AS A BIOMARKER IN JUVENILE DERMATOMYOSITIS

A. Van Ruyen-Kerkhof. Pediatric Immunology and Rheumatology, Wilhelmina children’s Hospital of the University Medical Center Utrecht, Utrecht, Netherlands

Background: Juvenile dermatomyositis (JDM) is a rare systemic immune-mediated disease involving skin and muscle. A high disease burden exists with risk of both under- and overtreatment due to the lack of reliable biomarkers.

Methods: A multiplex immunoassay was performed in a discovery cohort for plasma levels of 45 proteins related to inflammation in 25 well-defined JDM patients, determined by clinical activity and treatment.

Results: Subsequent results were validated in two independent international external and internal validation cohorts (n=125).

In a longitudinal cohort (n=30), the performance of this biomarker over time was assessed with a median 2.8 years follow-up.

Conclusion: Galectin-9 and CXCL10 are robust biomarkers for disease activity in JDM. A short-term implementation into clinical practice is feasible and can facilitate individualised treatment.

Disclosure of Interest: None declared


FRIDAY, 15 JUNE 2018

Triple T: T cells, technologies and therapies

SP0130

TOWARDS T CELL TOLERANCE IN RHEUMATOID ARTHRITIS

R. Thomas. Diamantina Institute, University of Queensland, Brisbane, Australia

Disease modifying strategies are available for treatment of rheumatoid arthritis (RA), and good response rates are achieved. However, limitations include toxicity, a response rate ceiling, cost and rationing of biologic therapies, inability to cure or permanently reverse RA pathology, and inability to prevent disease. Immuno-therapies targeting checkpoint molecules are markedly changing the landscape of clinical oncology. In autoimmune diseases such as RA, dendritic cells represent an important target for antigen-specific immunotherapy for T cell tolerance. Antigen-specific strategies promise greater specificity and safety, without general immune suppression, and thus the potential for intervention in at-risk subjects before disease onset. In a proof-of-concept trial, delivery of autoantigenic pep- tides and autologous tolerogenic dendritic cells was safe and had immunomodula- tory effects on T cells including reduction of effector T cells and a relative increase in regulatory T cells. We have developed and are trialling in RA patients, antigen-specific immunotherapy targeting dendritic cells in situ with liposomes encapsulat- ing autoantigenic peptide and calciotrol with the aim of antigen-specific T cell toler- ance. I will discuss the development of antigen-specific tolerance strategies and the parallel development of immune monitoring assays to determine T cell out- comes in clinical trials in RA.

Disclosure of Interest: R. Thomas

Grant/research support from: Janssen Biotech Inc, Consultant for: Janssen Biotech Inc


SP0131

ONLINE SOCIAL MEDIA PLATFORMS AND PUBLIC HEALTH INFORMATION: AN EXPLORATION INTO ARTHRITIS RELATED VIDEOS ON YOUTUBE IN 2017

E. Hera. The University of Southampton, Southampton, UK

Background: YouTube is one of the most used social media platforms from a desktop computer. YouTube provides a virtual platform that allows users to upload and view video content. Due to this functionality, YouTube is a valuable method for sharing and disseminating health information.

Methods: Patient and public involvement (PPI) representatives contributed to defining terms likely to be used by members of the public with arthritis searching for self-management strategies on YouTube. These included ‘joint pain’, ‘knee pain’, ‘hip pain’, ‘hand pain’ AND ‘helping’ or ‘improving’. From each of these search terms the top 10 videos sorted by view count were chosen. Videos were included if the content was related to arthritis, in English and published in 2017.

Results: Eighty videos were retrieved, 7 videos were irrelevant, 9 were duplicates and 11 were non-English language videos. Sixty-three videos were included for analysis. From the top fifty videos (sorted by view count), “Herbal Medicine” (n=14; 28%) was the most common category, followed by “Exercise and Stretch- ing” (n=12; 24%). The most watched video relating to the self-management of arthritis was related to “Herbal Medicine” with a view count close to two million (n=1,930,805) within the four months since it had been posted online. Twenty-five (40%) of the arthritis management related videos originated from the USA, with the UK producing only one video. Fifteen (30%) of the videos had been posted by self-reported health professionals. Nineteen (38%) of the videos were commercial.

Conclusion: Sharing of health information on YouTube is unregulated. The most accessed videos include alternative approaches to self-management and are not posted by registered health care professionals (HCPs). Whilst a wide range of arthritis-related videos were retrieved, few were created by HCPs or reputable health care organisations. YouTube is a powerful tool for people with arthritis to